Shanghai Kaibao Pharmaceutical (300039) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.042x

Based on the latest financial reports, Shanghai Kaibao Pharmaceutical (300039) has a cash flow conversion efficiency ratio of 0.042x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥190.98 Million ≈ $27.95 Million USD) by net assets (CN¥4.55 Billion ≈ $665.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 300039 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Shanghai Kaibao Pharmaceutical - Cash Flow Conversion Efficiency Trend (2006–2024)

This chart illustrates how Shanghai Kaibao Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Shanghai Kaibao Pharmaceutical Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Shanghai Kaibao Pharmaceutical ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Chengdu KSW Technologies Co. Ltd. A
SHG:688283
0.038x
Arizona Sonoran Copper Company Inc
TO:ASCU
-0.001x
Zhejiang Xiantong Rubber&Plastic Co Ltd
SHG:603239
0.061x
Reservoir Media Inc
NASDAQ:RSVR
0.034x
Ricegrowers Ltd
AU:SGLLV
0.122x
Ardmore Shipping Corporation
F:A61
0.041x
Sri Trang Agro-Industry Public Company Limited
BK:STA-R
0.237x
Talon Metals Corp
TO:TLO
-0.005x

Annual Cash Flow Conversion Efficiency for Shanghai Kaibao Pharmaceutical (2006–2024)

The table below shows the annual cash flow conversion efficiency of Shanghai Kaibao Pharmaceutical from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Shanghai Kaibao Pharmaceutical.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥4.10 Billion
≈ $600.40 Million
CN¥278.95 Million
≈ $40.82 Million
0.068x -28.35%
2023-12-31 CN¥4.03 Billion
≈ $590.13 Million
CN¥382.66 Million
≈ $56.00 Million
0.095x -5.19%
2022-12-31 CN¥3.76 Billion
≈ $550.36 Million
CN¥376.42 Million
≈ $55.08 Million
0.100x +141.71%
2021-12-31 CN¥3.04 Billion
≈ $445.57 Million
CN¥126.08 Million
≈ $18.45 Million
0.041x -57.41%
2020-12-31 CN¥2.58 Billion
≈ $377.29 Million
CN¥250.65 Million
≈ $36.68 Million
0.097x -25.23%
2019-12-31 CN¥2.57 Billion
≈ $376.00 Million
CN¥334.09 Million
≈ $48.89 Million
0.130x +23.16%
2018-12-31 CN¥2.49 Billion
≈ $363.65 Million
CN¥262.36 Million
≈ $38.39 Million
0.106x +1.62%
2017-12-31 CN¥2.37 Billion
≈ $346.14 Million
CN¥245.76 Million
≈ $35.96 Million
0.104x -27.40%
2016-12-31 CN¥2.20 Billion
≈ $321.97 Million
CN¥314.88 Million
≈ $46.08 Million
0.143x -12.25%
2015-12-31 CN¥2.01 Billion
≈ $293.47 Million
CN¥327.08 Million
≈ $47.86 Million
0.163x +8.85%
2014-12-31 CN¥1.88 Billion
≈ $275.78 Million
CN¥282.38 Million
≈ $41.32 Million
0.150x -10.95%
2013-12-31 CN¥1.61 Billion
≈ $235.02 Million
CN¥270.23 Million
≈ $39.54 Million
0.168x -1.89%
2012-12-31 CN¥1.42 Billion
≈ $207.61 Million
CN¥243.32 Million
≈ $35.61 Million
0.171x +132.79%
2011-12-31 CN¥1.33 Billion
≈ $195.27 Million
CN¥98.31 Million
≈ $14.39 Million
0.074x +360.54%
2010-12-31 CN¥1.24 Billion
≈ $181.01 Million
CN¥19.79 Million
≈ $2.90 Million
0.016x -65.23%
2009-12-31 CN¥1.15 Billion
≈ $167.72 Million
CN¥52.74 Million
≈ $7.72 Million
0.046x -68.76%
2008-12-31 CN¥126.92 Million
≈ $18.57 Million
CN¥18.70 Million
≈ $2.74 Million
0.147x -51.29%
2007-12-31 CN¥76.96 Million
≈ $11.26 Million
CN¥23.27 Million
≈ $3.41 Million
0.302x -42.84%
2006-12-31 CN¥37.24 Million
≈ $5.45 Million
CN¥19.70 Million
≈ $2.88 Million
0.529x --

About Shanghai Kaibao Pharmaceutical

SHE:300039 China Drug Manufacturers - Specialty & Generic
Market Cap
$652.05 Million
CN¥4.46 Billion CNY
Market Cap Rank
#11086 Global
#3135 in China
Share Price
CN¥4.26
Change (1 day)
-2.74%
52-Week Range
CN¥4.26 - CN¥6.96
All Time High
CN¥12.44
About

Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and… Read more